SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Viatris Inc. and Blueprint Medicines Corporation have showcased contrasting trajectories in their SG&A expenditures.

Viatris Inc.: A Steady Climb

From 2014 to 2023, Viatris Inc. has seen a consistent increase in SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a growth of over 200% from their 2014 figures, reflecting their expansive operational strategies and market penetration efforts.

Blueprint Medicines: A Rapid Surge

Conversely, Blueprint Medicines Corporation has experienced a more dramatic rise, with SG&A expenses skyrocketing from $7.89 million in 2014 to nearly $295 million in 2023. This exponential growth, over 3,600%, underscores their aggressive investment in marketing and administrative capabilities to support their innovative drug pipeline.

Both companies illustrate unique approaches to managing SG&A costs, offering valuable insights into strategic financial planning in the pharmaceutical sector.